Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.57 |
| ▸ | FFAR2 | O15552 | 11/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483272 | 0.89 | KCNH2 (0.59) | KCNH2SCN3AFFAR2PRMT5TRPC6 | |
| SCHEMBL2837773 | 0.83 | KCNH2 (0.66) | KCNH2SCN3AFFAR2 | |
| SCHEMBL1104551 | 0.81 | KCNH2 (0.51) | KCNH2SCN3AFFAR2PRMT5TRPC6 | |
| SCHEMBL2833224 | 0.80 | KCNH2 (0.57) | KCNH2SCN3APRMT5TRPC6S1PR1 | |
| SCHEMBL2839989 | 0.78 | KCNH2 (0.54) | KCNH2SCN3APRMT5TRPC6S1PR1 | |
| SCHEMBL2835713 | 0.78 | KCNH2 (0.61) | KCNH2SCN3APRMT5TRPC6ALDH1A1 | |
| SCHEMBL2836952 | 0.77 | KCNH2 (0.83) | KCNH2SCN3APRMT5TRPC6S1PR1 | |
| SCHEMBL2837757 | 0.77 | KCNH2 (0.55) | KCNH2SCN3APRMT5TRPC6S1PR1 | |
| SCHEMBL2836386 | 0.77 | KCNH2 (0.58) | KCNH2SCN3AFFAR2 | |
| SCHEMBL2832640 | 0.77 | KCNH2 (0.63) | KCNH2SCN3AFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | KCNH2 3260/4885SCN3A 2696/4885FFAR2 1237/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | KCNH2 15/4885SCN3A 11/4885FFAR2 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.